Replies to post #14808 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Easka, regarding Corti gout, the have no competition from Acthar with over 9 million patient affected by Gout and Corti 1ml selling for approx. $7,000 . If one only 0.5 % of this patient population is captured you are looking $315 million in revenue. Being able to be administered in the physician office, I think you will see uptake where standard of case is not working. We should see the proceeds from the Oakville plant in Q1 earnings. We may also see Sammy and Company get some earn out money.

I see guidance being raised in each quarter, even without acquiring a rare disease asset.
.